CLRB · Cellectar Biosciences, Inc.
$1.40
-0.11 (-7.28%)
At close · Oct 8
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.”View the 10-Q filed Aug 13, 2026
Market Cap
$13.33M
Shares
9.45M
Volume · Oct 8
169.7K
Avg daily vol (3M)
63.36K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.40
Open$1.57
Day$1.34–1.57
52W close$1.40–4.98
Avg vol 30d65K
Short int191K · 2.0% float · 4.6d
Short vol54%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 5 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-70.6%
Trailing year
Short interest
2.0%
Latest settlement · 4.6 days to cover
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. Cellectar initiated site activation for its confirmatory Phase 3 trial of iopofosine I-131 in Waldenström macroglobulinemia and remains on track to submit an NDA in mid-2027 under the FDA's accelerated approval pathway. The company also presented strong CLOVER WaM data at ASCO (79.2% MRR, 100% clinical benefit rate) and strengthened its balance sheet via an oversubscribed financing providing up to $140 million, though quarterly net loss widened to $6.9 million and R&D spend rose.
Bullish
- + Initiated site activation for confirmatory Phase 3 of iopofosine I-131 in WM with NDA submission planned mid-2027 under FDA accelerated approval
- + Reported strong CLOVER WaM data at ASCO in patients treated post-BTKi, including 79.2% MRR, 87.5% ORR, 100% clinical benefit rate, and durable responses
- + Completed an oversubscribed financing in May providing up to $140 million, including $35 million up front, strengthening the balance sheet to cash of $34.0 million
- + 12-month CLOVER WaM follow-up showed median duration of response of 17.8 months with VGPR/CR rate rising to 14.5%, reinforcing durability of iopofosine benefit
Bearish
- − Quarterly net loss widened to $6.9 million from $5.4 million a year earlier
- − R&D expenses nearly doubled year-over-year to $4.6 million as the company ramps Phase 3 and CLR 125 activities
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−50%
below
Price vs 50-day avg
−39%
below
RSI (14)
14
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−41%
trailing
6-month return
−52%
trailing
YTD return
−53%
this year
Relative strength
−61%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+53% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.02% of float · ▲ +14.5% MoM · 4.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
29 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
EPS growth
+80%
Y/Y
Free cash flow
$-23.1M
Balance sheet
$3.6M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−72%
past year
ATR
10.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−50%
Bearish
Price vs 50-day avg
−39%
Bearish
RSI (14)
14
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+53% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.02% of float · ▲ +14.5% MoM · 4.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
29 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $5
vs 200-day avg -50%
vs 50-day avg -39%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Clinical benefit rate | 100% | Q2 FY2026 | — |
| Disease control rate | 84.6% | Q2 FY2026 | — |
| Major response rate (MRR), partial response (PR) or better | 79.2% | Q2 FY2026 | — |
| Median duration of response (DOR) | 16 | Q2 FY2026 | — |
| Overall response rate (ORR) | 87.5% | Q2 FY2026 | — |
| Overall response rate (ORR) - multiple myeloma study | 15.4% | Q2 FY2026 | — |
| Overall response rate (ORR) among evaluable patients receiving at least 60 mCi | 30% | Q2 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLRB
this stock
Cellectar Biosciences, Inc.
|
$13.33M | -52.5% | — | — | 2.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.0% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLRB | -25.1% | -40.9% | -52.1% | -23.9% | -52.5% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -26.4% | -43.1% | -61.0% | -25.4% | -66.0% |